Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is developing a two-pronged approach to tackle neurological disorders, focusing on multiple sclerosis (MS) and the acute effects of alcohol intoxication. The company's pipeline addresses areas where existing treatments fall short, aiming to improve outcomes for millions of patients globally.
Multiple sclerosis, a debilitating autoimmune disease affecting an estimated 2.9 million people worldwide—including about one million in the United States—is a primary target. Quantum BioPharma's lead candidate, Lucid-MS, is a patented new chemical entity that takes a fundamentally different approach from existing therapies. Unlike current treatments that primarily modulate the immune system, Lucid-MS is designed to promote remyelination, the process of repairing damaged nerve insulation. This could potentially slow or reverse disease progression. Supporting the phase 2 development of Lucid-MS is an ongoing imaging collaboration with Massachusetts General Hospital, which will help assess the drug's effects on myelin repair.
The second program addresses the acute cognitive and physiological effects of alcohol intoxication. The company has developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce hangover symptoms. While not a treatment for alcohol use disorder, unbuzzd targets a common unmet need for individuals seeking to mitigate the immediate effects of alcohol consumption.
These two programs highlight Quantum BioPharma's strategy of targeting neurological conditions with high unmet medical need. MS affects a significant young adult population, with diagnosis typically occurring between ages 20 and 50, and women are affected at twice the rate of men. The current standard of care includes disease-modifying therapies that reduce relapse rates but do not reverse damage. Lucid-MS's potential to promote remyelination could represent a paradigm shift in MS treatment.
For further information on Quantum BioPharma, visit the company's newsroom at https://ibn.fm/QNTM.
